Clinical Trials - June 13, 2016
Results about Novo’s semaglutide
Novo Nordisk’s semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes. Findings from two phase 3a clinical trials for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, were presented at the American Diabetes Association 76th Scientific Sessions. In the […]
Clinical Trials - June 11, 2016
Novo’s Victoza reduce risk of major cardiovascular events
Novo Nordisk has announced that Victoza (liraglutide) significantly reduced the risk of the composite primary endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke by 13% vs placebo (95% confidence interval [CI]: 0.78; 0.97, p=0.01), when added to standard of care in 9,340 adults with type 2 diabetes at high CV […]
Clinical Trials - May 30, 2016
Novo’s Semaglutide shows positive results
Novo Nordisk’s Semaglutide demonstrates superior glycaemic control vs insulin glargine U100 in adults with type 2 diabetes shows a new study. Findings from a phase 3a clinical trial for semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue, demonstrated that treatment with semaglutide, administered once-weekly, significantly improved glycaemic control compared to insulin glargine U100 in adults with […]
Drug Development Pharma - May 25, 2016
Novo’s IDegLira receives positive vote
Novo Nordisk has announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval of IDegLira for the treatment of adults with type 2 diabetes. IDegLira is a once-daily, single injection fixed combination of insulin degludec (Tresiba) and liraglutide (Victoza) for the treatment of adults […]
Pharma Business - May 20, 2016
Novo Nordisk files for US approval of long-acting factor IX
Novo Nordisk has announced the submission to the US Food and Drug Administration (FDA) of the Biologics License Application for the approval of long-acting factor IX, nonacog beta pegol. Nonacog beta pegol is a glycopegylated recombinant factor IX with a significantly improved pharmacokinetic (PK) profile, developed for patients with haemophilia B. The filing of nonacog beta pegol […]
Pharma Business - April 21, 2016
Novo Nordisk plans investment in France
Novo Nordisk has announced that it plans to invest more than 100 million euros in production facilities at its site in Chartres, France. The new facilities will be built on Novo Nordisk’s existing 31,000 m2 site in Chartres, which produces a range of the company’s insulin products as well as FlexPen. Novo Nordisk has invested 300 […]
